Clinical trials: Thromboembolic Disease

Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke

Registry on WATCHMAN Outcomes in Real-Life Utilization

• Completed
• Age: 18 years and older
• Observational study
• Medical device
• Results posted

The WATCHMAN LAA Closure Technology is designed to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism.

Trial name

EWOLUTION (NCT01972282)

Testing

WATCHMAN Left Atrial Appendage Closure

Where

47 sites in Belgium, France and 11 more

Volunteers

1,025 people

Sponsor

Boston Scientific Corporation